Trial Profile
An open label, randomized, phase III study, evaluating the efficacy of a Combination of Apalutamide with Radiotherapy and LHRH Agonist in high-risk postprostatectomy biochemically relapsed prostate cancer patients
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary) ; LHRH receptor agonists
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms CARLHA-2
- Sponsors UNICANCER
- 22 Sep 2020 Status changed from suspended to recruiting.
- 24 Jan 2020 Status changed from not yet recruiting to recruiting.
- 26 Nov 2019 Status has been changed to not yet recruiting.